New drug may help liver transplant patients avoid bleeding complications

NCT ID NCT07600905

Completed Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether the drug avatrombopag can safely and effectively raise platelet counts in people who develop dangerously low platelets after a liver transplant. Researchers compared 67 patients who received the drug with 67 similar patients who got standard care. The goal was to see if the drug could reduce bleeding and the need for transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Avatrombopag (a drug that helps the body make more platelets)
What this could lead to: If it works, this could offer a new treatment option for dangerous low platelet counts after liver transplant, reducing bleeding and the need for blood transfusions.
What could go wrong: This is a small, retrospective study, not a large controlled trial. The results may not apply to all patients, and the drug could have side effects like blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANATATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postoperative Complications thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER TRANSPLANATATION POSTOPERATIVE COMPLICATION SEVERE THROMBOCYTOPENIA

Contacts and locations

Locations

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.